Understanding Crimean-Congo Hemorrhagic Fever

From The Unknown Diseases File

JOSHUA POWELL
MAR 14, 2025 • PAID

The Scary World of Zoonotic Diseases

From The Unknown Diseases File

Upsplash

Crimean-Congo hemorrhagic fever is a severe illness caused by the CCHF virus (CCHFV). As the name suggests, it was first recognized in Crimea in 1944, with scientists later discovering the same disease in the Congo, leading to its compound name.

The disease spreads primarily through tick bites, specifically from the *Hyalomma* tick species, which serves as both a reservoir and vector for the virus. Unlike many other dangerous viruses that have limited geographical spread, CCHF appears across a vast territory including Africa, the Middle East, Asia, and parts of southern and eastern Europe.

Several factors make CCHF particularly worrisome:

High fatality rate: Without proper treatment, roughly 30% of infected individuals will die from the disease.

Expanding risk zone: Climate change and other environmental factors are helping the *Hyalomma* tick expand its range, placing new populations at risk who have no prior

exposure or immunity.

Limited medical countermeasures: Currently, there are no licensed vaccines or specific antiviral medications approved for treating CCHF. Treatment typically consists of supportive care to manage symptoms while the patient's immune system fights the infection.

Transmission risk: Beyond tick bites, the virus can spread through contact with infected animal blood during slaughter or through exposure to bodily fluids from infected patients, putting healthcare workers at particular risk.

What makes this virus particularly interesting to scientists is its unusual behavior across species. CCHF virus can infect many different animals without causing them serious harm. Livestock including cattle, sheep, and goats often carry the virus with no obvious symptoms, serving as "amplifying hosts" that help spread the disease.

Humans, however, are a different story. When the virus jumps to people, it can trigger a severe and potentially fatal illness. This stark difference in how the virus affects various species remains one of the central mysteries researchers are working to understand.

Adding another layer of complexity, not all infected humans develop severe disease. Many individuals experience mild symptoms or no symptoms at all (subclinical infections). Scientists believe these subclinical cases are significantly underreported and may represent a substantial portion of all infections.

For those who do develop symptoms, CCHF typically progresses through several phases:

1. **Incubation period**: Lasting 1–13 days depending on how infection occurred (shorter for tick bites, longer for contact with infected materials)
2. **Pre-hemorrhagic phase**: Sudden onset of fever, headache, muscle pain, dizziness, neck pain, and eye sensitivity to light
3. **Hemorrhagic phase**: Appearing around day 3–5 of illness, patients may develop tiny red spots (petechiae), bruising, nosebleeds, and bleeding from the gums and other sites
4. **Recovery or fatal outcome**: Patients who survive typically begin improving around day 10–11 after symptom onset

Researchers face several obstacles in studying CCHF. The virus has an unusually complex genetic structure compared to related viruses in the *Bunyavirales* order. Its genome consists of three segments (small, medium, and large), with many viral proteins having unclear functions in how the virus causes disease.

Due to its high fatality rate and risk of person-to-person transmission, the virus must be handled in specialized high-containment laboratories (biosafety level 4), which

limits the number of research facilities that can work with live CCHFV.

The past decade has brought encouraging advances. Scientists have developed improved animal models that better mimic human disease, allowing for more relevant studies of how the virus causes illness. These models have already yielded important insights into CCHF's disease mechanisms.

Several candidate vaccines and antiviral treatments have shown promising results in these preclinical models. Some potential treatments target the virus directly, while others focus on modulating the body's immune response to prevent the excessive inflammation that contributes to severe disease.

Translating these scientific advances from laboratory to clinic represents the next critical step in combating CCHF. Developing effective treatments and vaccines would dramatically reduce the toll of this disease, especially in regions with limited healthcare resources where outbreaks can be particularly devastating.

Equally important is improving surveillance and public health measures. Many CCHF cases likely go undiagnosed due to limited awareness among healthcare providers and lack of diagnostic capabilities in affected regions. Better detection would provide a clearer picture of the disease's true impact and help target prevention efforts.

For individuals in affected regions, awareness and prevention remain crucial. Simple measures can significantly reduce risk:

- Using insect repellents and covering exposed skin when in areas where ticks may be present
- Carefully checking for and properly removing attached ticks
- Wearing gloves and protective clothing when handling animals or animal tissues
- Following proper hygiene and infection control practices in healthcare settings

As our global climate continues to change and human populations expand into new territories, diseases like CCHF may become increasingly relevant to public health. By advancing our understanding of this virus now, we prepare ourselves to better respond to both current outbreaks and future challenges.

Joshua Powell is a healthcare writer and researcher whose work has been published in prestigious outlets including The New England Journal of Medicine and by Hachette Book Group. He focuses on critical public health issues, from HIV/AIDS to the opioid epidemic. In 2017, LinkedIn recognized Powell as one of the Top 10 influencers in healthcare and awarded him their "Top Voice" distinction. Contact: jdpowell65@gmail.com

Powell House Press

← Previous

Next →

Discussion about this post

Comments Restacks

Write a comment...